CClinicalTrials.gg
Status unknownNCT04268238Updated Feb 13, 2020

Pain Control in Dentin Hypersensitivity in Patients With MIH

A Phase 1/2 interventional study of Hygiene Guidance and Sealant Application in Hypersensitivity Dentin, sponsored by University of Nove de Julho. Status unknown. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-13.

Sponsored by University of Nove de Julho · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2020), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

This study aims to evaluate the effectiveness of different protocols in controlling dentin hypersensitivity in patients with teeth affected by MIH. The subjects will be randomly designated in four experimental groups, according to different treatments. Pain will be assessed with the visual analog scale (Visual Analogue Scale - VAS), after stimulation with air from the triple syringe and and an exploratory probe at the time of (initial) recruitment, immediately after treatment, after 1 week and 1 month, 3 and 6 months after treatment.

02

Conditions studied

  • Hypersensitivity Dentin
03

In context

Dentin Sensitivity

283 studies on the registry are indexed under Dentin Sensitivity; 45 are open to participants now.

This study's planned enrollment of 140 is above the median of 60 across 274 interventional studies indexed under Dentin Sensitivity.

Browse Dentin Sensitivity studies →

Lead sponsor

University of Nove de Julho is the lead sponsor of 239 studies on the registry; 51 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 1 (13%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Be between 18 and 35 years old;
  • Present good general health;
  • Present at least one tooth with dentin hypersensitivity reported in the cervical region, which must have a graduated sensitivity equal to or greater than 4 in the VAS scale.

Exclusion criteria

Exclusion Criteria:

  • Present active caries lesions or restoration defects in the tooth to be analyzed;
  • Present sufficient dentin loss that requires restorative treatment or periodontal surgery;
  • Volunteers who underwent any professional desensitizer treatment in the last 6 months;
  • Volunteers who used desensitizing pastes in the 3 months;
  • Volunteers who were using anti-inflammatory or analgesic drugs at the time of recruitment;
  • Volunteers who are pregnant or breastfeeding.
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Control group

    Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate). Afterwards, this group will receive no treatment. Instead of the sealant, water will be used and the laser will remain with power 0W, that is, there will be no light emission, giving the group the characteristic of the control group, no treatment.

    Procedure: Hygiene Guidance

  • Experimental
    Sealant group

    In this group, besides the instructions described in the control group, the teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal (sealant) for 5 seconds to the tooth surface and light curing for 20 seconds.

    Procedure: Hygiene Guidance · Procedure: Sealant Application

  • Experimental
    Low Level Laser Group

    In this group, besides the instructions described in the control group, volunteers will receive irradiation with AsGaAl laser, wavelength of 780 nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, energy density of 35 J/cm2 (considering a spot size of 0.028 cm2 of this equipment), the dose will be 1 J per point. The irradiation will be performed at a cervical, an apical point and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.

    Procedure: Hygiene Guidance · Radiation: Low Level Laser Application

  • Experimental
    Low Level Laser + Sealant Group

    In this group, patients will receive the treatments described in Control group, Sealant group and Low Level Laser Group.

    Procedure: Hygiene Guidance · Procedure: Sealant Application · Radiation: Low Level Laser Application

Interventions

  • ProcedureHygiene Guidance

    Two weeks before the start of the study, the volunteers will go through a wash out period, where they should only use oral care products donated by the researchers, which should be used until the end of the study. The oral hygiene kit will contain 1 toothbrush (Professional Lab Series, Colgate Palmolive), 1 toothpaste without desensitizing agent, but with fluorine (Elmex) and 1 dental floss (Colgate).

  • ProcedureSealant Application

    Permaseal (Ultradent) is an unloaded resin based on methacrylate and photopolymerizable. The teeth that will be sealed will be isolated. 35% phosphoric acid will be applied for 20 seconds and then it will be necessary to wash and dry the tooth surface. Apply a thin layer of PermaSeal for 5 seconds to the tooth surface and light curing for 20 seconds. After that, it is necessary to evaluate occlusion.

  • RadiationLow Level Laser Application

    Volunteers will receive irradiation with AsGaAl laser, wavelength of 780nm (Laser XT Therapy, DMC, São Carlos, SP) with fixed power of 100mW, density of energy of 35 J/cm2 (considering a spot size of 0.028cm2 of this equipment), the dose will be 1 J per point. Irradiation will be performed at a cervical, an apical point, and another point exactly on the injury, totaling a dose of 3J. Treatment should be performed in 3 sessions with an ideal 72-hour interval between them.

06

What researchers measure

Primary outcomes

  1. Change in Pain Evaluated by a Visual Analog Scale (VAS)

    Pain will be assessed with the visual analogue scale (Visual Analogue Scale - VAS), after stimulation with air from the triple syringe and an explorer probe.

    Time frame: Baseline, immediately after treatment, 1 week, 1, 3 and 6 months after treatment.

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04268238
Lead sponsor
University of Nove de Julho
Responsible party
Sandra Kalil Bussadori (Principal Investigator, University of Nove de Julho) — Principal investigator
First posted
Feb 13, 2020
Start date
Mar 20, 2020 (estimated)
Primary completion
Nov 20, 2020 (estimated)
Completion
Dec 20, 2020 (estimated)
Last update
Feb 13, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion